This website uses cookies

We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. We will only use cookies based on your decision.

How are you testing your NASH patients?

Watch our interview with Dr. Arun Sanyal

ELF Physician Brochure
  • The Enhanced Liver Fibrosis (ELF) Test is the first routine, standardized, direct-biomarker panel for prognostic risk assessment in patients with advanced fibrosis due to NASH.
  • ELF is the first and only in vitro diagnostic to be granted De Novo Marketing Authorization by the FDA for prognosis of patients with advanced fibrosis due to NASH.
  • The widely studied ELF Test can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker.

Comorbidities 

The risk of developing liver disease is compounded by metabolic diseases such as diabetes, obesity, and high blood pressure.  Recent data trends suggest a startling increase in these conditions, meaning liver disease testing should be a top priority in the minds of physicians across the country.


<p>Arun J. Sanyal, MD</p>

Please complete the form below to be included in future email communications

By completing the form below, you are requesting to be added to our list for email communications. The information you provide below will be processed as described further in the Privacy Notice.

*Required

1
2
3
4
5
6
7
Subscription Button Icon
Be the first to know about our events, training, and news